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Among all DDS, peptide amphiphiles (PAs) have been emerged as effective tools for drug transporting applications. 2 PAs are typically composed of hydrophobic and charged segments. 3 The lipophilic compartment can be synthesized by using either long chain fatty acids or amino acids carrying hydrophobic residues such as tryptophan (W), phenylalanine (F), and isoleucine (I) in the structure. The hydrophobic portion of PAs is responsible for the entrapment of drugs and enhances the permeability of the carrier into the cell membrane. Additionally, the positively charged block of the PAs is composed of cationic amino acids such as arginine (R) and lysine (K). The positively charged unit of PAs deals with its binding to negatively charged elements in the phospholipid membrane including heparin and phosphate moieties. 4, 5 Due to the biodegradability and bioactivity of PAs, they have been used for the delivery of a broad range of cargos including stem cells, 6 proteins, 7 oligonucleotides, 8 phosphopeptides, 9 and anticancer drugs. [10] [11] [12] [13] Thus, the design and synthesis of novel PAs as highly efficient tools in modern drug delivery development have become a subject of major interest for researchers. PAs have been shown to improve the cellular uptake of various drugs through non-covalent entrapment. Because of unique properties of PAs, the loading and release of cargo molecules (drugs and/or biomolecules) are rapid since there is no covalent conjugation between the cargo molecules and the carrier. A simple physical mixing is sufficient for the loading of the cargo molecules because the hydrophobic segments of PAs entrap the hydrophobic drug through noncovalent interaction. Another significant advantage of non-covalent loading approach is the smoothness of the release process. Due to the absence of the covalent binding between drug and carrier, the system does not suffer from issues related to unpredictable intracellular release of the conjugated drugs. 14 However, design and architecture of the charged amino acids sequence along with the degree of hydrophobicity are critical to control the function of the carrier. Several new therapeutic candidates are hydrophobic or anionic showing poor solubility in the aqueous phase or limited membrane translocation, respectivley. 15 Thus, design of novel PAs with optimal molecular transporter properties is urgently needed.
We have previously reported the design and synthesis of short cationic linear peptide analogs (LPAs, prepared as Arg-C n -Arg-C n -Lys, where C n represented an alkyl chain containing n = 5, 7, or 11 methylenes). Among all synthesized peptides, a fluorescently conjugated LPA-C 11
(F′-LPA-C 11 ) demonstrated significant cellular uptake compared to the shorter LPAs. Thus, we have found that the chemical, physical, and biological properties of LPAs can be controlled by manipulating the chain length in the backbone and number or sequence of amino acids in the structure. 14 However, no study was performed on the role of the side chain manipulation of the amino acids.
To address the question that whether the side chain length can affect the cellular penetration of the PAs, four PAs derivatives containing arginine and lysine conjugated with fatty acyl groups of different chain lengths namely PA1: R-K(C 14 )-R, PA2: R-K(C 16 )-R, PA3: K(C 14 )-R-K(C 14 ), and PA4: K(C 16 )-R-K(C 16 ), where C 16 = palmitic acid and C 14 = myristic acid, were synthesized through Fmoc chemistry. The presence of two C 16 chains was found to be critical for the PAs transporter activity. To the best of our knowledge, this is the first report of the synthesis and comparative biological evaluation of PAs of this class.
EXPERIMENTAL SECTION

General
Reactions were carried out in Bio-Rad polypropylene columns by shaking and mixing using a Other chemicals and reagents were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). Fmoc deprotection at each step was carried out using piperidine in DMF (20%). The crude peptides were purified by using a reversed-phase Hitachi HPLC (L-2455) on a ZORBAX SB-C3 column, (4.6 mm × 25 cm, 5 µm) and a gradient system. The peptides were separated by eluting the crude peptides at 10.0 mL/min using a gradient of 0-100% acetonitrile (0.1% trifluoroacetic acid (TFA)) and water (0.1% TFA) over 60 min, and then were lyophilized to yield cyclic peptides. The purity of final products (≥95%) was confirmed by analytical HPLC. The analytical HPLC was performed on a Hitachi analytical HPLC system using a C18 Shimadzu Premier 3 µm with the free side chains of lysine was carried out using DIPEA in DCM as a coupling reagent for 3 h. The 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) side chain deprotection was accomplished with the mixture of TFA (13.5 mL)/thioanisole (750 µL)/anisole (300 µL)/DTT (450 mg) for 2 h. The peptide was separated by eluting the crude peptides at 10.0 mL/min using a gradient of 0-100% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min, and then was lyophilized. 
R-K(
Fluorescently-Labeled Conjugate of PA4 (F′
[F′-PA4] was synthesized using Fmoc-Lys(Mtt)-Wang resin (loading 0.35 mmol/g, 0.5 mmole, 1.43 g). The Fmoc group was deprotected using 20% piperidine followed by coupling with Fmoc-Arg(Pbf)-OH. The amino acid sequence was assembled followed by the deprotection of the attached Fmoc group to the N-terminal. The free NH 2 group was coupled with Fmoc-βAla-OH on the resin to be used as a linker. After the lysine side chain orthogonal protection, the Mtt groups were deprotected on the solid phase resin using a cleavage cocktail, TFA: The data presented were based on the mean fluorescence signal for 10,000 cells collected. All assays were performed in triplicate.
To perform the time-dependent assay, CCRF-CEM (1 × 10 7 cells) was taken in 6-well plates in serum-free RPMI medium. Then the fluorescence-labeled PA, F′-PA4 (5 µM), was added to the different wells in serum-free media at different periods of time. The plates were incubated for 10 min, 30 min, 1 h, and 2 h at 37 °C. Cells and 5-(6)-carboxyfluorescein (FAM, 5 µM) were used as negative controls. After the desired incubation time, the media containing the fluorescently-labeled peptide was removed. The washing procedure and instrument settings of the experiment were carried out as described above.
Cellular Uptake Studies in the Presence of Inhibitors. Human leukemia adenocarcinoma cells
(CCRF-CEM) were seeded in six well plates (1 × 10 7 cells/well) in serum-free RPMI medium.
The cells were pre-incubated by various inhibitors including, nystatin (50 µg/ml), chloroquine 
Cytotoxicity of PAs
The cytotoxicity of all synthesized PAs were evaluated in SK-OV-3, CCRF-CEM, and HCT-116 cancer cells at different concentrations (10-100 µM) after 24 h incubation time ( Figure   S1 ). Among all PAs, PA4 was found to be less toxic compared to other PAs reducing cell proliferation by 12, 3, and 1% in CCRF-CEM, HCT-116, and SK-OV-3 cell lines at a concentration of 100 µM, respectively. Among all PAs, PA1 showed higher toxicity reducing cell proliferation of HCT-116, CCRF-CEM, and SK-OV-3 cells by 15, 20, and 24% in respectively. Similarly, the cytotoxicity results at 50 µM of PAs showed that increasing the number of aliphatic side chains reduces the toxicity of the peptide and the compounds were less toxic at this concentration (Figure 2 ). The concentration of 50 µM of PAs was used for further cell-based studies. 
Drug Loading
Dox was used as a model drug for the quantitative loading studies. The loading of Dox was carried out based on previously reported method. 18 Dox solution (100 µL, 100 µM) was mixed with PA4 solution (400 µL, 500 µM) to obtain 1:10 molar ratio. A dialysis membrane was used to quantify the amount of the unloaded Dox. After 24 h stirring in water as media around the dialysis bag, the loading efficiency was found to be 56.7%. These data indicate that PA4 has The molecular transporting efficiency of PA4 for the delivery of large-sized biomolecules was evaluated by using a cell-impermeable negatively charged phosphopeptide as a model biomolecule using flow cytometry. Although phosphopeptides are valuable probes for studying the protein-protein interactions, they have found limited applications due to their low cell permeability. They do not cross the cell-membrane readily because of the presence of the negatively charged phosphate group. PEpYLGLD is a sequence that mimics the pTyr 1246 of ErbB2 and is responsible binding to the Chk SH2 domain. 22 The cellular uptake of F′-PEpYLGLD was monitored in the presence of all PAs including PA1, PA2, PA3, and PA4 in CCRF-CEM cells. FACS analysis showed that among all PAs, PA4 enhanced the uptake of F′-PEpYLGLD by 12.6-fold compared to that of the drug alone, suggesting that this system could function as a delivery tool for F′-PEpYLGLD ( Figure 5 ). However, the cellular uptake of F′-PEpYLGLD was not enhanced in the presence of other PAs, such as PA1, PA2, or PA3. These results are consistent with the cellular uptake studies of lamivudine that described above, confirming the potential of PA4 in improving the cellular uptake No green fluorescence was observed for the parent fluorescence-labeled phosphopeptide,
suggesting that F′-PEpYLGLD alone did not cross the membrane because of the presence of negatively charged phosphate group in the structure. As it is shown in Figure 6 , the cell nuclei 
Cellular Uptake of PA4
To confirm the internalization of PA4 alone, fluorescence-labeled PA4 (F′-PA4), F′-K(C 16 )-R-K(C 16 ), was prepared as described above. Incubation of F′-PA4 (5 µM) with CCRF-CEM cells for 2 h showed 7.5-fold higher cellular uptake compared to the FAM (5 µM) alone, thus suggesting the peptide structure is crucial for enhanced intracellular permeability (Figure 7 ).
The cellular uptake of F′-PA4 was found to be time-dependent and rapid even after 10 min. Understanding the mechanism(s) of the drug cellular uptake has been investigated as one of the important implications for peptide-mediated drug delivery and toxicity. Endocytosis as an energy-dependent process has been introduced as one of the major mechanisms of drug uptake.
Different mechanistic pathways could be involved in drug uptake by cells such as phagocytosis, micropinocytosis, and receptor-mediated endocytosis (RME) including clathrin-mediated, caveolae-mediated, and caveolae/clathrin independent endocytosis. 23 Here, the intracellular uptake of fluorescein-labeled peptide, F′-PA4 (5 µM) was evaluated quantitatively in the presence of several inhibitors including, nystatin, chloroquine, chlorpromazine, methyl-β-cyclodextrin, and 5-(N-ethyl-N-isopropyl)-amiloride (EIA) to investigate the responsible pathway(s) for the uptake.
Chloroquine is a lysosomotropic agent with proportional basic and hydrophobic
properties. This compound can cause the pH drop in endosome and block the endosome fusion.
Thus, molecular cargos stay in the endosome for a prolonged period. Furthermore, chloropromazine causes the inhibition of clathrin-mediated pathway through translocating clathrin and responsible associated adaptin (PA-2) complex located on the plasma membrane.
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As it is clear in Figure 9 , the intracellular uptake of F′-PA4 was significantly decreased in CCRF-CEM cells in the presence of different endocytic inhibitors including chloroquine and chloropromazine by 3-and 2-fold, respectively, after 2 h incubation, suggesting that the clathrinmediated pathway is one of the major mechanisms of cellular uptake.
Furthermore, sodium azide is used to block the ATP production by oxidative phosphorylation. In the presence of sodium azide and at 4 ºC, the cellular uptake of F′-PA4 was dropped dramatically, suggesting that the ATP depletion can be the significantly responsible in the internalization process. The presence of the EIA, nystatin, and methyl-β-cyclodextrin did not inhibit the cellular uptake of F′-PA4 proposing that lipid-raft-dependent micropinocytosis, and phagocytosis pathways may not be responsible in the endocytosis process. These results showed that the energy dependent pathways and mainly endocytosis pathways are responsible for transporting the drug across the cell membrane. The combination of arginine and palmitic acid in the structure of the PA4 makes the PA an optimal structure compared to other synthesized peptides for crossing over the cellular membrane. The interactions of arginine residues with the corresponding negatively charged phospholipids in lipid bilayer could be critical to trigger the internalization of PA4 into the cell membrane. Hydrophobic interactions generated by palmitic acid carbon chain and the lipids can potentially distort the outer phospholipid monolayer. This process will be followed by PA internalization and enhanced cellular uptake of the cargo molecules. The length of the carbon chain in PA4 is an important parameter that can alter the efficiency of PAs uptake by cells. PA4 showed two maximum peaks at 203 nm and 218 nm, suggesting that the carrier does not form a classic secondary structure ( Figure 10 ). However, when PA4 was loaded with PEpYLGLD, the CD results showed a similar pattern to β-sheet by a maximum at 199 nm and a minimum at 216 nm, suggesting that the secondary structure formation upon binding with in PEpYLGLD. As it is shown in Figure 10 , PEpYLGLD did not show any specific secondary structure. These results confirmed that the interaction between the phosphopeptide and the carrier leads to the formation of a new secondary structure that could be a favorable secondary of Dox was released intracellularly within 2, 12, 24, and 48 h. These data suggest that Doxloaded PA4 can be used as a potential prodrug for the sustained release of Dox.
Antiproliferative Assay
To determine whether PA4 can be exploited for the delivery of biologically relevant doses of Dox to cells, the antiproliferative activity of Dox was evaluated in SK-OV-3 cells in the presence and absence of the peptide. The antiproliferative activity of Dox (5 µM) in the presence of the PA4 was improved by approximately 10% compared to that of Dox alone after 24 incubation ( Figure 11 ). molecules. Furthermore, PA4 showed minimal toxicity at 100 µM. PA4 was able to act as a molecular transporter of fluorescence-labeled 3TC and a phosphopeptide (PEpYLGLD)
intracellularly. High cellular internalization of the labeled drugs by PA4 suggests the potential application of PA4 as a molecular transporter. Confocal microscopy showed that PA4 deliver the majority of cargos to the cytoplasm in cells. The present results provide insights for further optimization of PAs in this class as cellular delivery transporter.
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